The high end of the cell phone market is a lucrative, but highly competitive space. Consumers have fairly straightforward choices when it comes to iPhones or Windows devices, but there are more confusing choices among the Android phones.
In this multipart review series, Motley Fool analysts Eric Bleeker and Rex Moore look at three of the Android giants -- the HTC One, Nexus 4, and Samsung Galaxy S4 -- and how they stack up against each other as well as the non-Android competition. In today's video, Eric and Rex introduce the phones and talk about the competitive landscape among the various players.
Dialing a different tune
Want to get in on the smartphone phenomenon? Truth be told,�one company�sits at the crossroads of smartphone technology as we know it. It's not your typical household name, either. In fact, you've probably never even heard of it! But it stands to reap massive profits NO MATTER WHO ultimately wins the smartphone war. To find out what it is,�click here�to access the "One Stock You Must Buy Before the iPhone-Android War Escalates Any Further..."
Top Integrated Utility Stocks To Own For 2015: Poseidon Nickel Ltd (POS)
Poseidon Nickel Limited is an Australia-based company engaged in exploration, mining and production of Nickel and other minerals. The Company�� Windarra nickel project, includes an implied ore reserve (mineable resource) of 3,446,000 ore tons at an average grade of 1.79% nickel for 61,500 nickel metal tons and has a mine life of six years. Cerberus is closely located to Poseidon�� existing operations approximately 10.5 kilometers south of the Mt Windarra nickel mine. In September 2011, Poseidon entered into an earn-in agreement with Magma Metals Limited (Magma) for nickel, copper and PGE rights to a tenement package adjoining its Windarra Nickel Project (WNP). The new tenements cover 203 square kilometers. The Company�� subsidiaries include Poseidon Nickel Atlantis Operations Pty Ltd, Poseidon Nickel Olympia Operations Pty Ltd and Wells Gold Corporation (International) Pty Ltd. Advisors' Opinion:- [By jaggom]
NetSuite acquired Retail Anywhere recently that sells point of sale (POS) retail software and software solutions to multi-channel retail stores. The acquisition allowed NetSuite to grow its presence in stores. Retail Anywhere�� cloud capabilities will compile transactions from across stores, and integrate them with back-end support systems of businesses and offer customers a complete solution.
Top 10 Healthcare Equipment Stocks To Invest In Right Now: Rosetta Genomics Ltd (ROSG)
Rosetta Genomics Ltd., incorporated on March 9, 2000, is seeking to develop and commercialize diagnostic tests based on discovered group of genes known as microRNAs. The Company has established a clinical laboratory improvement amendment (CLIA)-certified laboratory in Philadelphia, which enables it to develop, validate and commercialize its own diagnostic tests applying its microRNA technology. In July 2011, the Company launched its fifth product - miRview lung. As of December 31, 2011, the Company launched five tests based on its five microRNA technologies: miRview mets; miRview mets2; miRview squamous; miRview meso, and miRview lung.
Rimonim Consortium
In January 2011, the Company joined the Rimonim Consortium, which is supported by the Office of the Chief Scientist at the Ministry of Industry, Trade and Labor of the State of Israel, or the OCS. The purpose of the consortium is to develop RNA interference, or RNAi, -based therapeutics.
Rosetta Green
Rosetta Green Ltd. is an Israeli subsidiary of the Company, which was established to leverage its capabilities into the areas of cleantech and plant biotech by using its microRNA technologies to develop plants and algae more suitable for various applications, such as feedstocks for biofuels and agriculture. Research at the Rosetta Green project has been shown to develop algal strains with oil content, to discover potential novel microRNAs from commercially-important algae and to identify drought-regulated microRNAs in plants.
The Company competes with Pathwork Diagnostics, Inc., Biotheranostics, Inc., Combimatrix Corporation, Alnylam Pharmaceuticals, Inc., Asuragen Inc., Exiqon A/S, Life Technologies Corporation, Isis Pharmaceuticals, Merck & Co., Inc., Santaris Pharma A/S, and Regulus Therapeutics.
Advisors' Opinion:- [By Peter Graham]
The Q3 2014 earnings report for molecular diagnostic company Myriad Genetics, Inc (NASDAQ: MYGN) is due out after the market closes on Tuesday and things could get ugly since unlike potential diagnostic stock peers such as Rosetta Genomics Ltd (NASDAQ: ROSG) and mid cap diagnostic stock Quest Diagnostics Inc (NYSE: DGX), it�� the most shorted stock on the Nasdaq with short interest of 52.07%. Aside from the Myriad Genetics earnings report, it should be said that Rosetta Genomics Ltd last reported earnings on March 31st and those�earnings were for the full year 2013 while�Quest Diagnostics reported Q1 2014 earnings on April 24th that were a disappointment due to restructuring costs and harsh winter weather. However, Myriad Genetics has been the more interesting stock as Medicare reimbursement rate increases and the lost of a court bid to block competition while a patent-infringement case is pending have sent its shares all over the place.
Top 10 Healthcare Equipment Stocks To Invest In Right Now: Endocyte Inc.(ECYT)
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics. Its SMDCs target receptors that are over-expressed on diseased cells, relative to healthy cells. The company?s principal SMDC product candidate, EC145, has been evaluated in a randomized Phase II clinical trial for the treatment of women with platinum-resistant ovarian cancer, and it also completed a Phase II single-arm clinical trial for pre-treated non-small cell lung cancer. Its preclinical development products include EC0489 and EC0225, which are in Phase I clinical trial for the treatment of solid cancer tumors; EC17 that has completed Phase I clinical trial for the treatment of solid cancer tumors; EC0531, a tubulysin conjugate to treat solid tumors; and EC0746 and EC0565 foliate receptors for the reduction o f inflammation. The company?s products under development also comprise EC20, a proprietary companion imaging diagnostic product for the identification of folate receptor in cancer patients; EC1069 for prostate cancer therapy; and EC0652 that is in early clinical trials for use as a companion imaging diagnostic for SMDCs. Endocyte, Inc. was founded in 1995 and is headquartered in West Lafayette, Indiana.
Advisors' Opinion:- [By Jason Shubnell]
Endocyte (NASDAQ: ECYT) was down, falling 5.16 percent to $21.88 after the company priced 4.5 million shares of its common stock at $21.00 per share.
- [By Keith Speights]
I suspect that the drugs being reviewed by the FDA are more likely than not to receive approval. Merck and partner Endocyte (NASDAQ: ECYT ) are seeking European approval for ovarian cancer drug vintafolide based on early stage and mid-stage clinical trials only. While the drug shows considerable promise, there is always a risk that authorization could be denied.
- [By Jon C. Ogg]
Endocyte Inc. (NASDAQ: ECYT) is trading like the company is being acquired. This is proof that any biotech with great cancer drug news can run, regardless of market conditions. It and Merck & Co. (NYSE: MRK) have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion for conditional marketing approval of Vynfinit (or vintafolide) and companion imaging components, imaging agent Folcepri (or etarfolatide), and Neocepri (intravenous folic acid), for the treatment of adult patients with ovarian cancer in combination with pegylated liposomal doxorubicin (PLD).
Top 10 Healthcare Equipment Stocks To Invest In Right Now: Novatel Wireless Inc.(NVTL)
Novatel Wireless, Inc. provides wireless broadband access solutions for the mobile communications market worldwide. It operates in two segments, Mobile Computing Products and machine-to-machine (M2M) Products and Solutions. The Mobile Computing Products segment offers MiFi Intelligent Mobile Hotspots, which provide connectivity option for Wi-Fi-enabled devices, such as the iPad, Kindle, tablets, PCs, MP3 players, and gaming devices; USB and PC-Card modems for wireless access; and embedded modules for use in laptop PCs, netbooks, tablets, and other electronic products to provide wireless broadband access. This segment also offers MobiLink mobile communications software suite, an object-oriented application that enables access to connectivity features, such as SMS, multimedia messaging, and virtual private networking, as well as provides video telephony and wireless local area networks management capabilities; and MiFi DLNA Server, which operates on MiFi hotspots and enables user to access and play movies, music, and photos. It serves wireless operators, laptop PC and other original equipment manufacturers, distributors, and various companies in other vertical markets. The M2M Products and Solutions segment provides asset-management solutions utilizing wireless technology and M2M communications devices. It offers Spider MT, SA, and AT integrated solutions and accessories for monitoring and managing mobile and fixed assets, vehicle tracking and telemetric, and workforce tracking and management; Enabler III and HS embedded solutions for various products or equipment to communicate with other computers; and N4A software and design services, including software and design services primarily for asset management solutions. This segment serves transportation companies, industrial companies, manufacturers of medical devices and geographical-location aware devices, and providers of security systems. The company was founded in 1996 and is headquartered i n San Diego, California.
Advisors' Opinion:- [By Roberto Pedone]
Novatel Wireless (NVTL), provides wireless broadband access solutions for the mobile communications market worldwide. This stock closed up 4.1% to $2.01 in Thursday's trading session.
Thursday's Range: $1.90-$2.02
52-Week Range: $1.51-$3.55
Thursday's Volume: 279,000
Three-Month Average Volume: 147,319From a technical perspective, NVTL ripped higher here right above its 50-day moving average of $1.88 with above-average volume. This strong spike to the upside on Thursday is quickly pushing shares of NVTL within range of triggering a near-term breakout trade. That trade will hit if NVTL manages to take out some near-term overhead resistance levels at $2.10 to $2.11 with high volume.
Traders should now look for long-biased trades in NVTL as long as it's trending above its 50-day at $1.88 or above more near-term support at $1.74 and then once it sustains a move or close above those breakout levels with volume that hits near or above 147,319 shares. If that breakout triggers soon, then NVTL will set up to re-test or possibly take out its next major overhead resistance levels at $2.18 to $2.30. Any high-volume move above those levels will then give NVTL a chance to re-fill some of its previous gap-down-day zone from March that started at $2.85.
Top 10 Healthcare Equipment Stocks To Invest In Right Now: Cabot Corp (CBT)
Cabot Corporation (Cabot), incorporated in 1960, is a global specialty chemicals and performance materials company. The Company�� principal products are rubber and specialty grade carbon blacks, fumed metal oxides, inkjet colorants, aerogels and cesium formate drilling fluids. Cabot and its affiliates have manufacturing facilities and operations in the United States and approximately 20 other countries. The Company operates in four business segments: the Core Segment, the Performance Segment, the New Business Segment and the Specialty Fluids Segment. It is organized into three geographic regions: The Americas; Europe, Middle East and Africa, and Asia Pacific. On January 23, 2012, the Company sold its Supermetals Business to Global Advanced Metals Pty Ltd. On August 1, 2012, it acquired Norit.
Core Segment
Carbon black is a form of elemental carbon that is manufactured in a highly controlled process to produce particles and aggregates of varied structure and surface chemistry, resulting in many different performance characteristics for a variety of applications. Its rubber blacks products are used in tires and industrial products. The Company owns, or has a controlling interest in, and operates plants that produce rubber blacks in Argentina, Brazil, Canada, China, Colombia, the Czech Republic, France, Indonesia, Italy, Japan, Malaysia, The Netherlands and the United States.
Performance Segment
The Performance Segment consists of two product lines: specialty grades of carbon black and thermoplastic concentrates; and fumed silica, fumed alumina and dispersions thereof. In each product line, it designs, manufactures and sells materials that deliver performance in a range of customer applications across the automotive, construction and infrastructure, and electronics and consumer products sectors. In addition, Cabot manufactures and sources thermoplastic concentrates and compounds that are marketed to the plastics industry. The Company owns, or has a ! controlling interest in, and operates plants that produce specialty grades of carbon black in China, The Netherlands and the United States. Its products are produced in facilities that it owns, or has a controlling interest in, located in Belgium, China and the United Arab Emirates. The Company also owns, or has a controlling interest in, manufacturing plants that produce fumed metal oxides in the United States, China, the United Kingdom and Germany. During the fiscal year ended September 30, 2011 (fiscal 2011), it closed its masterbatch manufacturing facility in Grigno, Italy.
New Business Segment
The Company�� New Business Segment consists of the Inkjet Colorants, Aerogel, Cabot Superior MicroPowders and Cabot Elastomer Composites Businesses. During fiscal 2011, its Cabot Elastomer Composites Business became part of its New Business Segment. The Company produces and sells aqueous inkjet colorants primarily to the inkjet printing market. Its inkjet colorants are produced for various inkjet printing applications, including small office and home office, corporate office, and commercial and industrial printing, as well as for other applications. Its inkjet colorants are manufactured at its facility in Haverhill, Massachusetts.
Cabot�� aerogel is a hydrophobic, silica-based particle with a high surface area that is used in a variety of thermal insulation and specialty chemical applications. In the construction industry, the product is used in insulative composite building products and translucent skylight, window, wall and roof systems for insulating eco-daylighting applications. In the oil and gas industry, aerogel is used to insulate subsea pipelines. In the specialty chemicals industry, the product is used to provide matte finishing, insulating and thickening properties for use in a variety of applications. It manufactures its aerogel products at its facility in Frankfurt, Germany.
The Company manufactures its aerogel products at its facility in F! rankfurt,! Germany. Finished products for use in the oil and gas industry are fabricated at a facility in Billerica, Massachusetts. The principal area of commercial focus for Cabot Superior MicroPowders Business (CSMP) is in developing covert taggants for a range of anti-counterfeiting security applications. Development and manufacturing activities are conducted primarily at its facilities in Albuquerque, New Mexico and Mountain View, California. In addition to the carbon black the Company makes using conventional carbon black manufacturing methods, it has developed elastomer composite products that are compounds of natural latex rubber and carbon black made by a liquid phase process. Its Cabot Elastomer Composites Business (CEC) products are targeted for tire, defense, mining, automotive and aerospace applications. It manufactures CEC products at its facility in Port Dickson, Malaysia.
Specialty Fluids Segment
The Company�� Specialty Fluids Segment produces and markets cesium formate as a drilling and completion fluid for use primarily in high pressure and high temperature oil and gas well construction. It has a mine and a cesium formate manufacturing facility in Manitoba, Canada, as well as fluid blending and reclamation facilities in Aberdeen, Scotland and in Bergen and Kristiansund, Norway.
The Company competes with Aspen Aerogel, Inc.
Advisors' Opinion:- [By Victor Selva]
The company has a current ratio of 17.8% which is higher than the industry mean of 6.55%. Also, it's higher than the one registered by Akzo Nobel NV (AKZOY), Cabot Corporation (CBT) and Olin Corporation (OLN). For investors looking for a higher ROE, PPG Industries Inc. (PPG) could be the option.
- [By Eric Volkman]
Cabot (NYSE: CBT ) has elected not to shift its dividend policy for the time being. The company declared its latest common stock distribution, which is to be $0.20 per share paid on September 13 to shareholders of record as of August 30.�That amount matches each of the firm's previous five distributions, the most recent of which was handed out in the middle of last month. Prior to that, Cabot paid $0.18 per share.
Top 10 Healthcare Equipment Stocks To Invest In Right Now: EnteroMedics Inc.(ETRM)
EnteroMedics Inc., a clinical development stage medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity and associated co-morbidities, and other gastrointestinal disorders. The company?s proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. Its product under development is the Maestro System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. The company intends to market its products to potential referral source clinicians, including general practitioners, internists, endocrinologists, and nurses. It has collaboration agreement with Mayo Clinic and Australian Institute of Weight Control. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003 . EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.
Advisors' Opinion:- [By John Udovich]
On Tuesday, small cap EnteroMedics Inc (NASDAQ: ETRM) soared 63.5% after reporting new clinical trial data for its Maestro system that is designed to control obesity, meaning it might be time to take a closer look at the stock along with the performance of other small cap obesity drug or treatment players like Arena Pharmaceuticals, Inc (NASDAQ: ARNA), Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc (NASDAQ: VVUS).
- [By Roberto Pedone]
One under-$10 health care player that's starting to trend within range of triggering a big breakout trade is EnteroMedics (ETRM), which is engaged in design and development of devices that use neuroblocking technology to treat obesity, its associated co-morbidities and other gastrointestinal disorders. This stock has been hit hard by the sellers so far in 2013, with shares off sharply by 59%.
If you take a look at the chart for EnteroMedics, you'll notice that this stock recently formed a double bottom chart pattern $1 to $1.01 a share. Following that bottom, shares of ETRM have started to rip higher and trend back above its 50-day moving average at $1.08 a share with strong upside volume flows. This move is quickly pushing ETRM within range of triggering a big near-term breakout trade.
Traders should now look for long-biased trades in ETRM if it manages to break out above some near-term overhead resistances levels at $1.14 to $1.19 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 584,986 shares. If that breakout triggers soon, then ETRM will set up to re-test or possibly take out its next major overhead resistance levels at $1.37 to $1.47 a share. Any high-volume move above those levels will then give ETRM a chance to re-fill some of its previous gap down zone from February that started above $3 a share.
Traders can look to buy ETRM off weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average of $1.08 a share, or below more key near-term support at $1 a share. One can also buy ETRM off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top 10 Healthcare Equipment Stocks To Invest In Right Now: Canadian Utilities Ltd (CDUAF)
Canadian Utilities Limited is a holding company. The Company is engaged in Utilities (pipelines, natural gas and electricity transmission and distribution), Energy (power generation, natural gas gathering, processing, storage and liquids extraction), and Technologies (business systems solutions). The Company operates in threes segments: TCO Electric, ATCO Gas and ATCO Pipelines. ATCO Electric is engaged in the regulated business of transmitting and distributing electricity to 245 communities as well as rural areas in east-central and northern Alberta. ATCO Gas is engaged in the business of distributing natural gas throughout Alberta and in the Lloydminster area of Saskatchewan. ATCO Pipelines is a regulated business engaged in the transmission of natural gas in Alberta. ATCO Pipelines receives natural gas on its pipeline system at various gas processing plants and transports it to end users within the province or other pipeline systems for export out of the province. Advisors' Opinion:- [By John Heinzl]
Contrast that with a company such as Canadian Utilities (CDUAF), whose eight price targets range from $40 to $42. (The stock closed Friday at $38.08 [Canadian]). Such tight clustering of targets indicates that analysts have a high degree of conviction about the company's future earnings, which isn't surprising for a utility that throws off predictable cash flows.
No comments:
Post a Comment